Postpartum Hemorrhage Clinical Trial
Official title:
Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor A Randomized Controlled Study
The third stage is the interval between delivery of the infant and delivery of the placenta.
This stage averages 10 minutes and is considered prolonged if it lasts longer than 30
minutes, placental separation occurs as a result of continued uterine contractions,
continued contractions control blood loss by compression of spiral arteries and also result
in migration of the placenta into the lower uterine segment and then through the cervix.
The intra-umbilical vein injection of 10 IU of oxytocin is recommended as a first line of
treatment for retained placenta. Despite this recommendation, the method has yet to make its
way into routine practice, probably because of the lack of a large substantive randomized
controlled trial, and lingering doubts over which uterotonic to use and at what dosage.
The purpose of this study is to evaluate the effect of intraumbilical vein injection of
oxytocin on reducing the duration of the third stage of labor and the need for manual
delivery of placenta, ,in addition to reduce blood loss during third and fourth stage of
labor and decrease incidence of rtained placenta in comparison with inraumblical injection
of normal saline.
This is a prospective randomized control trial conducted at Ain Shams University Maternity
Hospital. This study included 240 term pregnant women in labor admitted to the labor ward,
They were divided into Two groups :
Group (A):
The experimental group, 10 units of oxytocin will be injected into the umbilical vein at the
most proximal site to the placenta after clamping and cutting of the umbilical cord.
Group (B):
The control group, 1 mL normal saline will be injected into the umbilical vein at the most
proximal site to the placenta after clamping and cutting of the umbilical cord.
Status | Recruiting |
Enrollment | 1 |
Est. completion date | March 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 14 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. 36 to 42 weeks gestational age. 2. Single alive fetus with cephalic presentation. 3. Parity 1 to 3. 4. Normal vaginal delivery. Exclusion Criteria: 1. Placenta Previa. 2. Placental Abruption . 3. Prolonged Labor ( > 20 h ) 4. History of Postpartum Hemorrhage or Antepartum Hemorrhage. 5. History of Cesarean delivery or any uterine scar . 6. Polyhydramnios . 7. Known uterine anomalies. 8. Coagulation disorders. 9. Abnormal placental adhesion. 10. Forceps or Vacuum delivery. 11. Chorioamninitis. 12. Multiple Gestations. 13. Accelerated Labor (< 3 h ). 14. Painless Labor with Epidural Anaethesia |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
Egypt | kareem Sami mostafa | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of the third stage of labor. | For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded. | more than 30 minutes, we will do manual separation of placenta | Yes |
Secondary | Hb difference before and 12 h after delivery. | before labor and after 12 hours after delievery | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 |